BY Scott Merville

An immunotherapy used against advanced non-small cell lung cancer is being tested at MD Anderson for a different job: preventing the disease from developing in people with pre-cancerous lung nodules.

The first-of-its-kind Phase II clinical trial is based on research into these precancerous growths by Jianjun Zhang, M.D., Ph.D., assistant professor of Thoracic/Head and Neck Medical Oncology.


An immunotherapy clinical trial uses the immune checkpoint blockade drug pembrolizumab against precancerous growths to prevent their evolution to lung cancer.

BY MD Anderson staff

During MD Anderson’s recent Moon Shots Program event, a new clinical trial aimed at detecting lung cancer at an earlier stage was highlighted...